The Journal of Nuclear Medicine - JNM

The Journal of Nuclear Medicine - JNM Founded in 1960, The Journal of Nuclear Medicine is the world’s leading nuclear medicine, molecular i

According to new data announced by Clarivate in the 2020 Journal Citation Reports™ (released in June 2021), JNM ranks third in impact among 134 medical imaging journals worldwide. Impact factor – 10.057
Five-year impact factor – 8.573
Immediacy index – 4.011
Total citations – 32,949
Eigenfactor Score – 0.03249
Article Influence Score – 2.19

Analysis of tumor changes from the first to the last ¹⁷⁷Lu-PSMA injections through high-speed whole-body 360° ¹⁷⁷Lu CZT ...
11/26/2025

Analysis of tumor changes from the first to the last ¹⁷⁷Lu-PSMA injections through high-speed whole-body 360° ¹⁷⁷Lu CZT SPECT recordings provides strong prognostic information about mCRPC patients. https://ow.ly/lCNP50XqISz

AI–assisted lesion-tracking analysis of PSMA PET is prognostic for overall survival in patients with mCRPC undergoing PS...
11/25/2025

AI–assisted lesion-tracking analysis of PSMA PET is prognostic for overall survival in patients with mCRPC undergoing PSMA radiopharmaceutical therapy. https://ow.ly/O4sm50XqIMR

11/24/2025

Invited Perspective: ¹⁷⁷Lu-PSMA-617 monotherapy is provocative but no standard of care for metastatic hormone-sensitive prostate cancer. https://ow.ly/FC5i50XqIKo

Can metastatic prostate cancer be effectively treated with ¹⁷⁷Lu-PSMA-617 before the administration of ADT? https://ow.l...
11/21/2025

Can metastatic prostate cancer be effectively treated with ¹⁷⁷Lu-PSMA-617 before the administration of ADT? https://ow.ly/YXgj50XqIHQ

State of the Art: Comparison, agreement, and significance cutoffs of ¹⁸F-flurpiridaz PET myocardial blood flow quantitat...
11/19/2025

State of the Art: Comparison, agreement, and significance cutoffs of ¹⁸F-flurpiridaz PET myocardial blood flow quantitation methods and software packages. https://ow.ly/ymJb50XqIyX

¹⁷⁷Lu-AKIR001 is a CD44v6-targeted radiopharmaceutical therapy with strong preclinical efficacy, specificity, and safety...
11/18/2025

¹⁷⁷Lu-AKIR001 is a CD44v6-targeted radiopharmaceutical therapy with strong preclinical efficacy, specificity, and safety, as well as broad tumor applicability. https://ow.ly/g9jx50XqIx3

Biochemical responses to rechallenge and extended ¹⁷⁷Lu-PSMA therapy are promising, with at least 50% reductions in PSA ...
11/17/2025

Biochemical responses to rechallenge and extended ¹⁷⁷Lu-PSMA therapy are promising, with at least 50% reductions in PSA levels observed in a significant proportion of highly selected patients. https://ow.ly/1YaU50XqIwb

High tracer accumulation in 70% of patients with untreated hepatocellular carcinoma suggests a possible use for PSMA-dir...
11/14/2025

High tracer accumulation in 70% of patients with untreated hepatocellular carcinoma suggests a possible use for PSMA-directed radiopharmaceutical therapy in an end-stage setting. https://ow.ly/PQ6q50XqIuQ

11/13/2025

LRRC15 at the crossroads: Radioimmunotherapy charts a potential path forward. https://ow.ly/2xzV50XqItm

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

PSMA PET staging is decreasing the use of surgical local therapy and increasing systemic therapy use in the Veterans Aff...
11/03/2025

PSMA PET staging is decreasing the use of surgical local therapy and increasing systemic therapy use in the Veterans Affairs system. https://ow.ly/Q7NK50Xif9q

Address

Reston, VA
20190

Alerts

Be the first to know and let us send you an email when The Journal of Nuclear Medicine - JNM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram